Phase III Study to Evaluate the Efficacy and Safety of AD-209

Phase 3UnknownNCT06348576

Addpharma Inc.280 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of AD-209

Condition or disease : hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

280

Conditions

Hypertension,Essential

Interventions

AD-209DRUG

PO, Once daily(QD), 8weeks

AD-2091DRUG

PO, Once daily(QD), 8weeks

AD-209 PlaceboDRUG

PO, Once daily(QD), 8weeks

AD-2091 Placebo

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Other inclusions applied Exclusion Criteria: * Orthostatic hypotension with symptom * Other exclusions applied

Locations (1)

Korea University Guro Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Change rate of MSSBP

Change from baseline in mean sitting systolic blood pressure

Time frame: Baseline, Week 8

Central Contacts

Kyung Tae Kim, D.V.M

CONTACT

82-031-891-5661 ktkim@addpharma.co.kr

Chang Gyu Park, M.D., Ph.D

CONTACT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.